We have developed several new biomarkers in patients with esophageal carcinoma. In this paper, we reviewed the clinical impact of serum autoantibodies, growth factors, blood counts, and other serum tumor markers. Methods Blood samples of patients with esophageal carcinoma were obtained before surgery and were stored at −80°C until the ELISA assay. Target tumor antigens for autoantibodies were SURF1, LOC, HOOK2, AGENCOURT, TROP-2, TRIM21, GLUT-1, Myomegalin, Makorin-1, CUEC-23, ECSA-1, p53, and NY-ESO-1. Growth factor-related molecules were followed; midkine, VEGF, PDECGF, and HGF. The other markers were followed; platelet, CRP, IAP, SCC-Ag, CYFRA21-1, and fibrinogen. Results A total of 24 biomarkers were evaluated for their clinical impact on patients’ survival and tumor stages. High positive rates, more than 40% were found in SURF1, Myomegalin, midkine, and HGF. Although the majority of autoantibodies did not have a prognostic impact, all the growth factors have a prognostic impact on patients’ survival. Lutine blood tests, such as platelet count, neutrophil-lymphocyte ratio, fibrinogen, and CRP, were also useful to predict prognosis. Conclusion We have evaluated the clinical impact of 24 new biomarkers, including 13 autoantibodies, for the patients with esophageal carcinoma. Although the autoantibodies were useful to detect relatively early stage of the disease, the prognostic impact of these biomarkers was limited. All growth factors were useful to predict patients’ survival.

中文翻译：

---

166 新生物标志物对食管癌患者的临床影响

我们在食管癌患者中开发了几种新的生物标志物。在本文中，我们回顾了血清自身抗体、生长因子、血细胞计数和其他血清肿瘤标志物的临床影响。方法食管癌患者术前采集血样，-80℃保存至ELISA检测。自身抗体的目标肿瘤抗原是 SURF1、LOC、HOOK2、AGENCOURT、TROP-2、TRIM21、GLUT-1、Myomegalin、Makorin-1、CUEC-23、ECSA-1、p53 和 NY-ESO-1。跟踪生长因子相关分子；中期因子、VEGF、PDECGF 和 HGF。紧随其后的是其他标记；血小板、CRP、IAP、SCC-Ag、CYFRA21-1 和纤维蛋白原。结果共评估了 24 种生物标志物对患者生存和肿瘤分期的临床影响。阳性率高，超过 40% 存在于 SURF1、Myomegalin、中期因子和 HGF。尽管大多数自​​身抗体对预后没有影响，但所有生长因子对患者的生存都有预后影响。Lutine 血液检查，如血小板计数、中性粒细胞-淋巴细胞比值、纤维蛋白原和 CRP，也可用于预测预后。结论 我们评估了包括 13 种自身抗体在内的 24 种新生物标志物对食管癌患者的临床影响。尽管自身抗体可用于检测疾病的相对早期阶段，但这些生物标志物的预后影响是有限的。所有生长因子都有助于预测患者的生存。中性粒细胞-淋巴细胞比率、纤维蛋白原和 CRP 也可用于预测预后。结论 我们评估了包括 13 种自身抗体在内的 24 种新生物标志物对食管癌患者的临床影响。尽管自身抗体可用于检测疾病的相对早期阶段，但这些生物标志物的预后影响是有限的。所有生长因子都有助于预测患者的生存。中性粒细胞-淋巴细胞比率、纤维蛋白原和 CRP 也可用于预测预后。结论 我们评估了包括 13 种自身抗体在内的 24 种新生物标志物对食管癌患者的临床影响。尽管自身抗体可用于检测疾病的相对早期阶段，但这些生物标志物的预后影响是有限的。所有生长因子都有助于预测患者的生存。